Welcome to DU! The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards. Join the community: Create a free account Support DU (and get rid of ads!): Become a Star Member Latest Breaking News General Discussion The DU Lounge All Forums Issue Forums Culture Forums Alliance Forums Region Forums Support Forums Help & Search
 

ehrnst

(32,640 posts)
Fri Aug 26, 2016, 08:06 AM Aug 2016

The Clinton Foundation and HIV AIDS medication

Last edited Fri Aug 26, 2016, 09:09 AM - Edit history (2)

For purposes of countering all the crap being thrown at Hillary because of Mylan fiasco - Bresch did not donate to the Clinton Foundation, Mylan, the company was a partner in providing lower priced anti-retroviral drugs to people with HIV AIDS:

Here is the press release that explains that relationship: https://www.clintonfoundation.org/main/news-and-media/press-releases-and-statements/press-release-president-clinton-pfizer-and-mylan-announce-new-agreements-to-lowe.html

Here is an explanation of how the Clinton Foundation created partnerships with pharmacuetical companies to provide a high volume of doses at lower profit margins (which may be at the root of some of the "Hillary's in bed with Big Pharma" fallacies).

The Clinton Foundation has focused its global health energies on reordering the marketplace for generic antiretroviral drugs (ARVs) for treating HIV in developing countries. The basic problem, according to its analysis, is a market failure. Pharmaceutical companies had adopted a "jewelry-store model" -- one based on high margins and low volume, pricing drugs high because they assumed there would be few buyers. This may make sense from a business perspective, but it makes no sense when trying to provide a social good. High prices for ARVs mean that developing-country governments and citizens cannot afford these drugs.

The Clinton Foundation's approach has been to reorient the market toward a "grocery-store model" -- low margins, high volume and certain payment. The foundation would negotiate lower prices for a consortium of states, which would then place orders with the manufacturers. The foundation does not buy drugs itself, but rather facilitates the opportunity for states to acquire these drugs at prices lower than those on the open market. In the process, the foundation creates a larger drug market, allowing pharmaceutical companies to profit from higher sales volumes, even if the margin on any individual order is lower.

This market-based approach has shown success. Since 2003, it has achieved price reductions for more than 40 different ARV formulations from eight different suppliers. The cost decreases have allowed more than 2 million people in developing countries to receive treatment. An independent evaluation published in 2009 in the Bulletin of the World Health Organization found that the Clinton Foundation's approach led to statistically significant price reductions for 9 of 13 antiretroviral drugs, reducing prices between 6 percent to 36 percent and increasing access better than other programs. With its efforts on ARVs, the Clinton Foundation's efforts have changed the supply side of the equation, altering the market incentives to encourage companies to provide goods in areas that they would otherwise consider unprofitable.


http://www.worldpoliticsreview.com/articles/7329/the-clinton-and-gates-foundations-global-health-superpowers
Latest Discussions»Retired Forums»2016 Postmortem»The Clinton Foundation an...